InflaRx - About the company
InflaRx is a public company based in Jena (Germany), founded in 2008 by Renfeng Guo and Niels Riedemann. It operates as a Developer of antibody therapeutics for inflammatory and immune diseases. InflaRx has raised $64.1M in funding from RA Capital Management and Bain Capital Life Sciences. The company has 3679 active competitors, including 1234 funded and 862 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Biogen.
Company Details
Developer of antibody therapeutics for inflammatory and immune diseases. The company focuses on the development of monoclonal antibodies that target activation products of the complement system for application in inflammatory diseases. The product pipeline inlcudes Vilobelimab for oncology, immuno-dermatology, and inflammatory diseases, and IFX002 C5a Inhibitor for chronic inflammatory and autoimmune diseases.
- Website
- www.inflarx.de/
- Registered Address
- Winzerlaer Strasse 2 07745 Jena
Key Metrics
Founded Year
2008
Location
Jena, Germany
Stage
Public
Total Funding
$64.1M in 4 rounds
Latest Funding Round
Investors
Ranked
216th among 3679 active competitors
Employee Count
46 as on Aug 31, 2026
Exit Details
Public
Legal entities associated with InflaRx
InflaRx is associated with 4 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Inflarx Nv CIN: 68904312 , Netherlands, Active | Jan 01, 2007 | - | - | - |
INFLARX PHARMACEUTICALS, INC. CIN: 32081879119 , United States, Active | Nov 10, 2021 | - | - | - |
Inflarx Gmbh CIN: Y1206_HRB502149 , Germany, Active | Dec 19, 2007 | - | - | |
Inflarx Gmbh CIN: HRB502149 , Germany, Active | Dec 18, 2007 | - | 56 (As on Dec 31, 2021) |
InflaRx's IPO details
InflaRx got listed on Nov 08, 2017.
Click here to take a look at InflaRx's IPO in detail
Sign up to download InflaRx's company profile
InflaRx's funding and investors
InflaRx has raised a total funding of $64.1M over 4 rounds. Its first funding round was on Mar 18, 2009. Its latest funding round was a Series D round on Oct 13, 2017 for $*****. 3 investors participated in its latest round. InflaRx has 5 institutional investors.
Here is the list of recent funding rounds of InflaRx:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 13, 2017 | 5059340 | Series D | 6647556 | 7461893 | 8975969 | 8707781 |
Jul 21, 2016 | 3674563 | Series C | 2227908 | 6516114 | 2245906 | 9484941 |
Jul 17, 2014 | 5747580 | Series B | 5897662 | 8042995 | 6201009 |
Access funding benchmarks and valuations. Sign up today!View details of InflaRx's funding rounds and investors
InflaRx's founders and board of directors
Founder? Claim ProfileThe founders of InflaRx are Renfeng Guo and Niels Riedemann.
Here are the details of InflaRx's key team members:
- Renfeng Guo: Co-Founder of InflaRx.
- Niels Riedemann: Co-Founder of InflaRx.
View details of InflaRx's Founder profiles and Board Members
InflaRx's employee count trend
InflaRx has 46 employees as of Aug 26. Here is InflaRx's employee count trend over the years:
Uncover InflaRx's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
InflaRx's Competitors and alternates
Top competitors of InflaRx include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of InflaRx, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
4th | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 75/100 | ||
5th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
6th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
7th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
8th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
9th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
216th | Developer of antibody therapeutics for inflammatory and immune diseases | $64.1M | 59/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on InflaRx's competitors? Click here to see the top ones
InflaRx's Investments and acquisitions
InflaRx has made no investments or acquisitions yet.
Reports related to InflaRx
Here is the latest report on InflaRx's sector:
News related to InflaRx
Filter this listMedia has covered InflaRx for a total of 8 events in the last 1 year, 4 of them have been about company updates and 1 about people movement.
•
•
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary SharesBusiness Insider•May 08, 2026•InflaRx
•
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal DiseasesGlobeNewswire•May 06, 2026•InflaRx
•
InflaRx N.V. Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswire•Apr 28, 2026•InflaRx
•
•
InflaRx Announces International Nonproprietary Name of Izicopan for INF904GlobeNewswire•Dec 11, 2025•InflaRx
•
•
InflaRx Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswire•Sep 12, 2025•InflaRx
•
•
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire•Aug 07, 2025•InflaRx
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about InflaRx
Explore our recently published companies
- Rupert Group - Lakeland based, 2004 founded, Unfunded company
- fab4minds - next generation business IT - Austria based, 2001 founded, Unfunded company
- Silion - China based, Public company
- Monster Meal - Iowa City based, 2003 founded, Acquired company
- BNPParel - France based, Unfunded company
- WiredInn Growth - Nigeria based, 2010 founded, Unfunded company
